Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06488950
EARLY_PHASE1

A Study of TIL in Advanced Solid Tumors (DFGD)

Sponsor: Shanghai Juncell Therapeutics

View on ClinicalTrials.gov

Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Official title: A Study Study of Tumor Infiltrating Lymphocytes Injection (GC101/203 TIL) in Patients With Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2023-04-01

Completion Date

2027-06-30

Last Updated

2025-12-16

Healthy Volunteers

No

Interventions

BIOLOGICAL

GC203 TIL(gene-edited TIL) or autologous TILs

the candidates will be assigned to GC203 TIL(gene-edited TIL) group or autologous TILs group according the volume of TIL sample

Locations (1)

Third Affiliated Hospital of Naval Medical University

Shanghai, China